Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.33 |
| ▸ | HRH1 | P35367 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL407322 | 0.80 | PDK1 (0.59) | PDK1NPC1KDM4EHPGDHSD17B10 | |
| SCHEMBL439305 | 0.79 | CDC7 (0.35) | PDK1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL462942 | 0.76 | LIMK1 (0.39) | PDK1SCN9ASCN3ASCN5ADRD2 | |
| SCHEMBL440402 | 0.75 | DGAT1 (0.44) | — | |
| SCHEMBL438511 | 0.75 | SMN1; SMN2 (0.39) | PDK1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL3533425 | 0.64 | RAB9A (0.50) | PDK1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL13314816 | 0.64 | RAB9A (0.50) | PDK1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL3538335 | 0.63 | ADRA2A (0.41) | PDK1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL3538338 | 0.62 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL13314812 | 0.62 | RAB9A (0.47) | NPC1RAB9ASMN1; SMN2KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | PDK1 377/4885SCN9A 1557/4885SCN3A 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.